In the BioHarmony Drug Report Database

"Preview" Icon

Epoprostenol

Flolan, Veletri (epoprostenol) is a small molecule pharmaceutical. Epoprostenol was first approved as Flolan on 1995-09-20. It is used to treat arteriosclerosis, peripheral vascular diseases, pulmonary hypertension, purpura, and respiratory distress syndrome amongst others in the USA. The pharmaceutical is active against prostaglandin E2 receptor EP1 subtype. In addition, it is known to target prostaglandin E2 receptor EP4 subtype and prostacyclin receptor. Flolan’s patent is valid until 2027-03-15 (FDA).

 

Trade Name

 

Flolan, Veletri
 

Common Name

 

epoprostenol
 

ChEMBL ID

 

CHEMBL1139
 

Indication

 

arteriosclerosis, peripheral vascular diseases, pulmonary hypertension, purpura, respiratory distress syndrome, systemic scleroderma
 

Drug Class

 

Prostaglandins

Image (chem structure or protein)

Epoprostenol structure rendering